Cargando…
Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
SIMPLE SUMMARY: Imatinib mesylate (IM, Gleevec) has remained first-line therapy for most gastrointestinal stromal tumor (GIST) patients since 2002. During this time, three additional inhibitors have been approved for treatment of IM-refractory tumors; however, disease stabilization for these agents...
Autores principales: | Kozinova, Marya, Joshi, Shalina, Ye, Shuai, Belinsky, Martin G., Sharipova, Dinara, Farma, Jeffrey M., Reddy, Sanjay S., Litwin, Samuel, Devarajan, Karthik, Campos, Alex Rosa, Yu, Yi, Schwartz, Brian, von Mehren, Margaret, Rink, Lori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345102/ https://www.ncbi.nlm.nih.gov/pubmed/34359600 http://dx.doi.org/10.3390/cancers13153699 |
Ejemplares similares
-
Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
por: Ye, Shuai, et al.
Publicado: (2021) -
Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors
por: Belinsky, Martin G., et al.
Publicado: (2013) -
Translation, Pdcd4 and eIF4A
por: Biyanee, Abhiruchi, et al.
Publicado: (2015) -
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013) -
Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
por: Belinsky, Martin G., et al.
Publicado: (2017)